

References

I-129

1. U.S. Food and Drug Administration (FDA). FDA approves Entyvio to treat ulcerative colitis and Crohn's disease. FDA News. Silver Spring, MD: FDA. May 2014.
2. Rezaie A. Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to antiTNF therapy in inflammatory bowel diseases. *Annals of Gastroenterology*. 2014;27:179-180.
3. Feagan BG, Rutgeerts P, Sands BE, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2013;369(8):699-710.
4. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med*. 2013;369:711-721.
5. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. *Ther Adv Gastroenterol*. 2015;8(2):66–82.
6. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology*. 2014;147:618–627.
7. Kawalec P, Mocko P, Pil A, et al. Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison. *Pharmacotherapy*. 2016;861-869.
8. Daumgart DC, Bokemeyer B, Brabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study. *Alimentary Pharmacology and Therapeutics*. 2016;1090-1102.
9. Singh H, Grewal N, Kumar EAH, Kakkar AK. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. *Journal of Natural Science, Biology & Medicine*. 2016;4-9.
10. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
11. Schneider AM, Weghuber D, Hetzer B, Entenmann A, Muller T, Zimmermann G, et al. Vedolizumab use after failure of TNF-alpha antagonists in children and adolescents with inflammatory bowel disease. *BMC Gastroenterology*. 2018;18(140):1-7.
12. Garnock-Jones, KP. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or crohn's disease. *BioDrugs*. 2015;29:57-67.
13. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and crohn's disease. *Gut*. 2017;66(5):839-851.
14. Entyvio™ (vedolizumab) intravenous injection. Takeda Pharmaceuticals America, Inc. Deerfield, IL. Revised 02/2018.
15. MICROMEDEX®SOLUTIONS Compendia. 2018. Vedolizumab.
16. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Vedolizumab. 2018.
17. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).